Plain-English translation of NCT06062966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called , which blocks a protein in the body that causes inflammation. The study is for people with advanced heart failure who are already taking IV medications (inotropes) to help their hearts pump. Researchers believe that reducing inflammation with this medication might make those IV drugs work better and help patients feel better with lower doses.
Many patients with end-stage heart failure depend on IV medications that stimulate the heart, but these drugs can cause serious side effects and only provide temporary relief. This medication may reduce the inflammation that makes hearts less responsive to these treatments, potentially offering a safer, more effective way to help these patients.
You likely qualify if…
You likely don't qualify if…
Participants will inject themselves with the medication daily at home. The study involves a screening visit to confirm eligibility, followed by regular clinic visits to monitor heart function, blood work, and how well the medication is working. You will also complete exercise tests (like a 6-minute walking test) to measure any improvement in your ability to be active, with total involvement lasting several weeks.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States